PPI Cuts Risk of Warfarin-Related Upper GI Bleeding

Share this content:
PPI Cuts Risk of Warfarin-Related Upper GI Bleeding
PPI Cuts Risk of Warfarin-Related Upper GI Bleeding

FRIDAY, Dec. 23, 2016 (HealthDay News) -- For patients beginning warfarin therapy, proton pump inhibitor (PPI) co-therapy is associated with reduced risk of upper gastrointestinal bleeding, according to a study published in the December issue of Gastroenterology.

Wayne A. Ray, Ph.D., of the Vanderbilt University School of Medicine in Nashville, Tenn., and colleagues conducted a retrospective cohort study of patients in Tennessee Medicaid and the 5 percent National Medicare Sample. A total of 97,430 new episodes of warfarin treatment were identified, with follow-up of 75,720 person-years.

The researchers found that there were 119 hospitalizations for upper gastrointestinal bleeding per 10,000 person-years of treatment among patients who took warfarin without PPI co-therapy. Patients who received PPI co-therapy had a 24 percent decreased risk (adjusted hazard ratio, 0.76; 95 percent confidence interval, 0.63 to 0.91). In this group there was no significant reduction in the risk of other gastrointestinal bleeding hospitalizations or non-gastrointestinal bleeding hospitalizations. For patients concurrently using antiplatelet drugs or nonsteroidal anti-inflammatory drugs (NSAIDs), there were 284 upper gastrointestinal bleeding hospitalizations per 10,000 person-years of warfarin treatment for those without PPI co-therapy. With PPI co-therapy the risk was reduced by 45 percent (hazard ratio, 0.55; 95 percent confidence interval, 0.39 to 0.77). For patients not using antiplatelet drugs or NSAIDs, PPI co-therapy had no significant protective effect (hazard ratio, 0.86; 95 percent confidence interval, 0.70 to 1.06).

"PPI co-therapy was associated with reduced risk of warfarin-related upper gastrointestinal bleeding," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »